Белгија - Енглески - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - irinotecan hydrochloride trihydrate 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - topoisomerase 1 (top1) inhibitors

Белгија - Енглески - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - irinotecan hydrochloride trihydrate 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - topoisomerase 1 (top1) inhibitors

Белгија - Енглески - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - irinotecan hydrochloride trihydrate 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - topoisomerase 1 (top1) inhibitors

Белгија - Енглески - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - irinotecan hydrochloride trihydrate 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - topoisomerase 1 (top1) inhibitors

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

accord healthcare limited - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml - irinotecan

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

hospira uk limited - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml - irinotecan

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: lactic acid; sorbitol; water for injections; sodium hydroxide; hydrochloric acid - irinotecan hydrochloride trihydrate is indicated as: - a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum; - a single agent for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-fluorouracil-based therapy.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: lactic acid; sorbitol; water for injections; sodium hydroxide; hydrochloric acid - irinotecan hydrochloride trihydrate is indicated as: - a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum; - a single agent for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-fluorouracil-based therapy.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: hydrochloric acid; lactic acid; sodium hydroxide; water for injections; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sorbitol; lactic acid - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.